Dedifferentiated Liposarcoma — Trials

Dedifferentiated Liposarcoma — Trials · CancerIndex

Clinical trials

Registered studies

35 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 19
Recruiting: 9
Ph III recruiting: 1
Growth YoY: —
Industry share: 16%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06422806	Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas	recruiting	Phase 3	365	National Cancer Institute (NCI)NIH	3	Sep 22, 2026	clinicaltrials
NCT05218499	Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma	completed	Phase 2 / Phase 3	400	Boehringer IngelheimINDUSTRY	22	Mar 2, 2026